A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD
subjects both male and female between the ages of 50-85. Nine normal controls will undergo
repeated whole body imaging for biodistribution and dosimetry estimation. Six other normal
healthy subjects will undergo heart imaging only. Six CAD subjects will undergo heart imaging
only.